Kiniksa (KNSA) PT Raised to $40 at JMP Securities, After Company Announces Phase 2 Clinical Trial Of Vixarelimab (KPL-716) In Prurigo Nodularis Meets Primary Efficacy Endpoint
Tweet Send to a Friend
JMP Securities analyst Liisa A ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
